Umbelliprenin and Chronic Lymphocytic Leukemia (CLL) Treatment - Gholami, Omid
21,99 €
inkl. MwSt.

Versandfertig in 1-2 Wochen
payback
11 °P sammeln
  • Broschiertes Buch

Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in western countries. One of the most important strategies in CLL chemotherapy is apoptosis induction in CLL cells. Over the last decades herbal medicines and their constituents attract the attentions for chemotherapy of CLL. Umbelliprenin is a sesquiterpene coumarin, that is synthesized by various Ferula species. Apoptosis induction and cytotoxicity toward cancerous cells by umbelliprenin, firstly showed in 2008. In my Ph.D thesis I studied the properties of apoptosis induction in CLL cell lines by umbelliprenin. For the…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in western countries. One of the most important strategies in CLL chemotherapy is apoptosis induction in CLL cells. Over the last decades herbal medicines and their constituents attract the attentions for chemotherapy of CLL. Umbelliprenin is a sesquiterpene coumarin, that is synthesized by various Ferula species. Apoptosis induction and cytotoxicity toward cancerous cells by umbelliprenin, firstly showed in 2008. In my Ph.D thesis I studied the properties of apoptosis induction in CLL cell lines by umbelliprenin. For the first time I should that umbelliprenin could induce apoptosis in CLL cell lines time- and dose- dependently. umbelliprenin and other natural coumarins are hopeful compounds in the future of CLL chemotherapy.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. Omid Gholami has completed his PhD at the age of 29 years from Shahid Beheshti University of Medical Sciences, Iran. He is a faculty member and assisstant professor in Sabzevar University of Medical Sciences, Iran. He has published more than 12 papers in reputed journals and has been serving as an editorial board member of repute.